1. Home
  2. SPPL vs CLGN Comparison

SPPL vs CLGN Comparison

Compare SPPL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPPL

SIMPPLE LTD.

HOLD

Current Price

$4.60

Market Cap

19.5M

Sector

N/A

ML Signal

HOLD

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

N/A

Current Price

$1.54

Market Cap

23.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPPL
CLGN
Founded
2016
2004
Country
Singapore
Israel
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
23.1M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SPPL
CLGN
Price
$4.60
$1.54
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$11.50
AVG Volume (30 Days)
4.1K
27.8K
Earning Date
04-10-2026
11-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,591,508.00
$2,475,000.00
Revenue This Year
N/A
$1,617.28
Revenue Next Year
N/A
$83.54
P/E Ratio
N/A
N/A
Revenue Growth
24.27
280.77
52 Week Low
$2.18
$1.30
52 Week High
$16.80
$4.98

Technical Indicators

Market Signals
Indicator
SPPL
CLGN
Relative Strength Index (RSI) 47.62 34.38
Support Level $4.30 $1.30
Resistance Level $5.36 $1.93
Average True Range (ATR) 0.36 0.15
MACD 0.04 -0.05
Stochastic Oscillator 46.48 28.52

Price Performance

Historical Comparison
SPPL
CLGN

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: